TY - JOUR AU - Jemal, A. AU - Siegel, R. AU - Xu, J. AU - Ward, E. PY - 2010 DA - 2010// TI - Cancer statistics, 2010 JO - CA Cancer J Clin VL - 60 UR - https://doi.org/10.3322/caac.20073 DO - 10.3322/caac.20073 ID - Jemal2010 ER - TY - JOUR AU - Bretthauer, M. PY - 2010 DA - 2010// TI - Evidence for colorectal cancer screening JO - Best Pract Res Clin Gastroenterol VL - 24 UR - https://doi.org/10.1016/j.bpg.2010.06.005 DO - 10.1016/j.bpg.2010.06.005 ID - Bretthauer2010 ER - TY - JOUR AU - Amado, R. G. AU - Wolf, M. AU - Peeters, M. AU - van Cutsem, E. AU - Siena, S. AU - Freeman, D. J. AU - Juan, T. AU - Sikorski, R. AU - Suggs, S. AU - Radinsky, R. PY - 2008 DA - 2008// TI - Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.14.7116 DO - 10.1200/JCO.2007.14.7116 ID - Amado2008 ER - TY - JOUR AU - de Gramont, A. AU - Figer, A. AU - Seymour, M. AU - Homerin, M. AU - Hmissi, A. AU - Cassidy, J. AU - Boni, C. AU - Cortes-Funes, H. AU - Cervantes, A. AU - Freyer, G. PY - 2000 DA - 2000// TI - Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer JO - J Clin Oncol VL - 18 ID - de Gramont2000 ER - TY - JOUR AU - Douillard, J. Y. AU - Siena, S. AU - Cassidy, J. AU - Tabernero, J. AU - Burkes, R. AU - Barugel, M. AU - Humblet, Y. AU - Bodoky, G. AU - Cunningham, D. AU - Jassem, J. PY - 2010 DA - 2010// TI - Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.27.4860 DO - 10.1200/JCO.2009.27.4860 ID - Douillard2010 ER - TY - JOUR AU - Hurwitz, H. AU - Fehrenbacher, L. AU - Novotny, W. AU - Cartwright, T. AU - Hainsworth, J. AU - Heim, W. AU - Berlin, J. AU - Baron, A. AU - Griffing, S. AU - Holmgren, E. PY - 2004 DA - 2004// TI - Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa032691 DO - 10.1056/NEJMoa032691 ID - Hurwitz2004 ER - TY - JOUR AU - Peeters, M. AU - Price, T. J. AU - Cervantes, A. AU - Sobrero, A. F. AU - Ducreux, M. AU - Hotko, Y. AU - Andre, T. AU - Chan, E. AU - Lordick, F. AU - Punt, C. J. PY - 2010 DA - 2010// TI - Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.27.6055 DO - 10.1200/JCO.2009.27.6055 ID - Peeters2010 ER - TY - JOUR AU - Saltz, L. B. AU - Clarke, S. AU - Diaz-Rubio, E. AU - Scheithauer, W. AU - Figer, A. AU - Wong, R. AU - Koski, S. AU - Lichinitser, M. AU - Yang, T. S. AU - Rivera, F. PY - 2008 DA - 2008// TI - Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.14.9930 DO - 10.1200/JCO.2007.14.9930 ID - Saltz2008 ER - TY - JOUR AU - van Cutsem, E. AU - Kohne, C. H. AU - Hitre, E. AU - Zaluski, J. AU - Chang Chien, C. R. AU - Makhson, A. AU - D’Haens, G. AU - Pinter, T. AU - Lim, R. AU - Bodoky, G. PY - 2009 DA - 2009// TI - Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer JO - N Engl J Med VL - 360 UR - https://doi.org/10.1056/NEJMoa0805019 DO - 10.1056/NEJMoa0805019 ID - van Cutsem2009 ER - TY - JOUR AU - Edwards, M. S. AU - Chadda, S. D. AU - Zhao, Z. AU - Barber, B. L. AU - Sykes, D. P. PY - 2012 DA - 2012// TI - A systematic review of treatment guidelines for metastatic colorectal cancer JO - Colorectal Dis VL - 14 UR - https://doi.org/10.1111/j.1463-1318.2011.02765.x DO - 10.1111/j.1463-1318.2011.02765.x ID - Edwards2012 ER - TY - JOUR AU - Gravalos, C. AU - Cassinello, J. AU - Fernandez-Ranada, I. AU - Holgado, E. PY - 2007 DA - 2007// TI - Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer JO - Clin Colorectal Cancer VL - 6 UR - https://doi.org/10.3816/CCC.2007.n.038 DO - 10.3816/CCC.2007.n.038 ID - Gravalos2007 ER - TY - JOUR AU - Wood, L. D. AU - Parsons, D. W. AU - Jones, S. AU - Lin, J. AU - Sjoblom, T. AU - Leary, R. J. AU - Shen, D. AU - Boca, S. M. AU - Barber, T. AU - Ptak, J. PY - 2007 DA - 2007// TI - The genomic landscapes of human breast and colorectal cancers JO - Science VL - 318 UR - https://doi.org/10.1126/science.1145720 DO - 10.1126/science.1145720 ID - Wood2007 ER - TY - JOUR AU - Lin, J. AU - Gan, C. M. AU - Zhang, X. AU - Jones, S. AU - Sjoblom, T. AU - Wood, L. D. AU - Parsons, D. W. AU - Papadopoulos, N. AU - Kinzler, K. W. AU - Vogelstein, B. PY - 2007 DA - 2007// TI - A multidimensional analysis of genes mutated in breast and colorectal cancers JO - Genome Res VL - 17 UR - https://doi.org/10.1101/gr.6431107 DO - 10.1101/gr.6431107 ID - Lin2007 ER - TY - JOUR AU - Bozic, I. AU - Antal, T. AU - Ohtsuki, H. AU - Carter, H. AU - Kim, D. AU - Chen, S. AU - Karchin, R. AU - Kinzler, K. W. AU - Vogelstein, B. AU - Nowak, M. A. PY - 2010 DA - 2010// TI - Accumulation of driver and passenger mutations during tumor progression JO - Proc Natl Acad Sci USA VL - 107 UR - https://doi.org/10.1073/pnas.1010978107 DO - 10.1073/pnas.1010978107 ID - Bozic2010 ER - TY - JOUR AU - Carter, H. AU - Chen, S. AU - Isik, L. AU - Tyekucheva, S. AU - Velculescu, V. E. AU - Kinzler, K. W. AU - Vogelstein, B. AU - Karchin, R. PY - 2009 DA - 2009// TI - Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-09-1133 DO - 10.1158/0008-5472.CAN-09-1133 ID - Carter2009 ER - TY - JOUR AU - Hunter, T. PY - 1998 DA - 1998// TI - The role of tyrosine phosphorylation in cell growth and disease JO - Harvey Lect VL - 94 ID - Hunter1998 ER - TY - JOUR AU - Hunter, T. PY - 1998 DA - 1998// TI - The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease JO - Philos Trans R Soc Lond B Biol Sci VL - 353 UR - https://doi.org/10.1098/rstb.1998.0228 DO - 10.1098/rstb.1998.0228 ID - Hunter1998 ER - TY - JOUR AU - Fearon, E. R. AU - Vogelstein, B. PY - 1990 DA - 1990// TI - A genetic model for colorectal tumorigenesis JO - Cell VL - 61 UR - https://doi.org/10.1016/0092-8674(90)90186-I DO - 10.1016/0092-8674(90)90186-I ID - Fearon1990 ER - TY - JOUR AU - Smith, A. J. AU - Stern, H. S. AU - Penner, M. AU - Hay, K. AU - Mitri, A. AU - Bapat, B. V. AU - Gallinger, S. PY - 1994 DA - 1994// TI - Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons JO - Cancer Res VL - 54 ID - Smith1994 ER - TY - JOUR AU - Ionov, Y. AU - Peinado, M. A. AU - Malkhosyan, S. AU - Shibata, D. AU - Perucho, M. PY - 1993 DA - 1993// TI - Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis JO - Nature VL - 363 UR - https://doi.org/10.1038/363558a0 DO - 10.1038/363558a0 ID - Ionov1993 ER - TY - JOUR AU - Pawson, T. PY - 2002 DA - 2002// TI - Regulation and targets of receptor tyrosine kinases JO - Eur J Cancer VL - 38 UR - https://doi.org/10.1016/S0959-8049(02)80597-4 DO - 10.1016/S0959-8049(02)80597-4 ID - Pawson2002 ER - TY - JOUR AU - Arora, A. AU - Scholar, E. M. PY - 2005 DA - 2005// TI - Role of tyrosine kinase inhibitors in cancer therapy JO - J Pharmacol Exp Ther VL - 315 UR - https://doi.org/10.1124/jpet.105.084145 DO - 10.1124/jpet.105.084145 ID - Arora2005 ER - TY - JOUR AU - Paez, J. G. AU - Janne, P. A. AU - Lee, J. C. AU - Tracy, S. AU - Greulich, H. AU - Gabriel, S. AU - Herman, P. AU - Kaye, F. J. AU - Lindeman, N. AU - Boggon, T. J. PY - 2004 DA - 2004// TI - EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy JO - Science VL - 304 UR - https://doi.org/10.1126/science.1099314 DO - 10.1126/science.1099314 ID - Paez2004 ER - TY - JOUR AU - Phipps, A. I. AU - Buchanan, D. D. AU - Makar, K. W. AU - Win, A. K. AU - Baron, J. A. AU - Lindor, N. M. AU - Potter, J. D. AU - Newcomb, P. A. PY - 2013 DA - 2013// TI - KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers JO - Br J Cancer VL - 108 UR - https://doi.org/10.1038/bjc.2013.118 DO - 10.1038/bjc.2013.118 ID - Phipps2013 ER - TY - JOUR AU - Safaee Ardekani, G. AU - Jafarnejad, S. M. AU - Tan, L. AU - Saeedi, A. AU - Li, G. PY - 2012 DA - 2012// TI - The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0047054 DO - 10.1371/journal.pone.0047054 ID - Safaee Ardekani2012 ER - TY - JOUR AU - Mao, C. AU - Zhou, J. AU - Yang, Z. AU - Huang, Y. AU - Wu, X. AU - Shen, H. AU - Tang, J. AU - Chen, Q. PY - 2012 DA - 2012// TI - KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0036653 DO - 10.1371/journal.pone.0036653 ID - Mao2012 ER - TY - JOUR AU - Gunby, R. H. AU - Sala, E. AU - Tartari, C. J. AU - Puttini, M. AU - Gambacorti-Passerini, C. AU - Mologni, L. PY - 2007 DA - 2007// TI - Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy JO - Anticancer Agents Med Chem VL - 7 UR - https://doi.org/10.2174/187152007784111340 DO - 10.2174/187152007784111340 ID - Gunby2007 ER - TY - JOUR AU - Moulder, S. L. AU - Craft, B. S. AU - Hortobagyi, G. N. PY - 2008 DA - 2008// TI - Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast cancer JO - Anticancer Agents Med Chem VL - 8 UR - https://doi.org/10.2174/187152008784533080 DO - 10.2174/187152008784533080 ID - Moulder2008 ER - TY - JOUR AU - Suda, K. AU - Mizuuchi, H. AU - Maehara, Y. AU - Mitsudomi, T. PY - 2012 DA - 2012// TI - Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation–diversity, ductility, and destiny JO - Cancer Metastasis Rev VL - 31 UR - https://doi.org/10.1007/s10555-012-9391-7 DO - 10.1007/s10555-012-9391-7 ID - Suda2012 ER - TY - JOUR AU - Lin, L. AU - Bivona, T. G. PY - 2012 DA - 2012// TI - Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients JO - Chemother Res Pract VL - 2012 ID - Lin2012 ER - TY - JOUR AU - Ozvegy-Laczka, C. AU - Cserepes, J. AU - Elkind, N. B. AU - Sarkadi, B. PY - 2005 DA - 2005// TI - Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters JO - Drug Resist Updat VL - 8 UR - https://doi.org/10.1016/j.drup.2005.02.002 DO - 10.1016/j.drup.2005.02.002 ID - Ozvegy-Laczka2005 ER - TY - JOUR AU - Lee, S. H. AU - Lopes de Menezes, D. AU - Vora, J. AU - Harris, A. AU - Ye, H. AU - Nordahl, L. AU - Garrett, E. AU - Samara, E. AU - Aukerman, S. L. AU - Gelb, A. B. PY - 2005 DA - 2005// TI - In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2129 DO - 10.1158/1078-0432.CCR-04-2129 ID - Lee2005 ER - TY - JOUR AU - Taeger, J. AU - Moser, C. AU - Hellerbrand, C. AU - Mycielska, M. E. AU - Glockzin, G. AU - Schlitt, H. J. AU - Geissler, E. K. AU - Stoeltzing, O. AU - Lang, S. A. PY - 2011 DA - 2011// TI - Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer JO - Mol Cancer Ther VL - 10 UR - https://doi.org/10.1158/1535-7163.MCT-11-0312 DO - 10.1158/1535-7163.MCT-11-0312 ID - Taeger2011 ER - TY - JOUR AU - Kim, K. B. AU - Chesney, J. AU - Robinson, D. AU - Gardner, H. AU - Shi, M. M. AU - Kirkwood, J. M. PY - 2011 DA - 2011// TI - Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-11-1747 DO - 10.1158/1078-0432.CCR-11-1747 ID - Kim2011 ER - TY - JOUR AU - Renhowe, P. A. AU - Pecchi, S. AU - Shafer, C. M. AU - Machajewski, T. D. AU - Jazan, E. M. AU - Taylor, C. AU - Antonios-McCrea, W. AU - McBride, C. M. AU - Frazier, K. AU - Wiesmann, M. PY - 2009 DA - 2009// TI - Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors JO - J Med Chem VL - 52 UR - https://doi.org/10.1021/jm800790t DO - 10.1021/jm800790t ID - Renhowe2009 ER - TY - JOUR AU - Tai, W. T. AU - Cheng, A. L. AU - Shiau, C. W. AU - Liu, C. Y. AU - Ko, C. H. AU - Lin, M. W. AU - Chen, P. J. AU - Chen, K. F. PY - 2012 DA - 2012// TI - Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3 JO - Mol Cancer Ther VL - 11 UR - https://doi.org/10.1158/1535-7163.MCT-11-0412 DO - 10.1158/1535-7163.MCT-11-0412 ID - Tai2012 ER - TY - JOUR AU - Huynh, H. AU - Chow, P. K. AU - Tai, W. M. AU - Choo, S. P. AU - Chung, A. Y. AU - Ong, H. S. AU - Soo, K. C. AU - Ong, R. AU - Linnartz, R. AU - Shi, M. M. PY - 2012 DA - 2012// TI - Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma JO - J Hepatol VL - 56 UR - https://doi.org/10.1016/j.jhep.2011.09.017 DO - 10.1016/j.jhep.2011.09.017 ID - Huynh2012 ER - TY - JOUR AU - de Menezes DE, L. AU - Peng, J. AU - Garrett, E. N. AU - Louie, S. G. AU - Lee, S. H. AU - Wiesmann, M. AU - Tang, Y. AU - Shephard, L. AU - Goldbeck, C. AU - Oei, Y. PY - 2005 DA - 2005// TI - CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-05-0358 DO - 10.1158/1078-0432.CCR-05-0358 ID - de Menezes DE2005 ER - TY - JOUR AU - Dey, J. H. AU - Bianchi, F. AU - Voshol, J. AU - Bonenfant, D. AU - Oakeley, E. J. AU - Hynes, N. E. PY - 2010 DA - 2010// TI - Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-4479 DO - 10.1158/0008-5472.CAN-09-4479 ID - Dey2010 ER - TY - JOUR AU - Chase, A. AU - Grand, F. H. AU - Cross, N. C. PY - 2007 DA - 2007// TI - Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome JO - Blood VL - 110 UR - https://doi.org/10.1182/blood-2007-02-074286 DO - 10.1182/blood-2007-02-074286 ID - Chase2007 ER - TY - JOUR AU - Oudard, S. AU - Thierry, A. AU - Jorgensen, T. J. AU - Rahman, A. PY - 1991 DA - 1991// TI - Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes JO - Cancer Chemother Pharmacol VL - 28 ID - Oudard1991 ER - TY - JOUR AU - Castellano, E. AU - Downward, J. PY - 2011 DA - 2011// TI - RAS interaction with PI3K: more than just another effector pathway JO - Genes Cancer VL - 2 UR - https://doi.org/10.1177/1947601911408079 DO - 10.1177/1947601911408079 ID - Castellano2011 ER - TY - JOUR AU - Eckert, L. B. AU - Repasky, G. A. AU - Ulku, A. S. AU - McFall, A. AU - Zhou, H. AU - Sartor, C. I. AU - Der, C. J. PY - 2004 DA - 2004// TI - Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-04-0396 DO - 10.1158/0008-5472.CAN-04-0396 ID - Eckert2004 ER - TY - JOUR AU - Repasky, G. A. AU - Chenette, E. J. AU - Der, C. J. PY - 2004 DA - 2004// TI - Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? JO - Trends Cell Biol VL - 14 UR - https://doi.org/10.1016/j.tcb.2004.09.014 DO - 10.1016/j.tcb.2004.09.014 ID - Repasky2004 ER - TY - JOUR AU - Parsons, D. W. AU - Wang, T. L. AU - Samuels, Y. AU - Bardelli, A. AU - Cummins, J. M. AU - DeLong, L. AU - Silliman, N. AU - Ptak, J. AU - Szabo, S. AU - Willson, J. K. PY - 2005 DA - 2005// TI - Colorectal cancer: mutations in a signalling pathway JO - Nature VL - 436 UR - https://doi.org/10.1038/436792a DO - 10.1038/436792a ID - Parsons2005 ER - TY - JOUR AU - Vivanco, I. AU - Sawyers, C. L. PY - 2002 DA - 2002// TI - The phosphatidylinositol 3-Kinase AKT pathway in human cancer JO - Nat Rev Cancer VL - 2 UR - https://doi.org/10.1038/nrc839 DO - 10.1038/nrc839 ID - Vivanco2002 ER - TY - JOUR AU - Duriez, P. J. AU - Shah, G. M. PY - 1997 DA - 1997// TI - Cleavage of poly (ADP-ribose) polymerase: a sensitive parameter to study cell death JO - Biochem Cell Biol VL - 75 UR - https://doi.org/10.1139/o97-043 DO - 10.1139/o97-043 ID - Duriez1997 ER - TY - JOUR AU - Kolinsky, K. AU - Shen, B. Q. AU - Zhang, Y. E. AU - Kohles, J. AU - Dugan, U. AU - Zioncheck, T. F. AU - Heimbrook, D. AU - Packman, K. AU - Higgins, B. PY - 2009 DA - 2009// TI - In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models JO - Mol Cancer Ther VL - 8 UR - https://doi.org/10.1158/1535-7163.MCT-08-0596 DO - 10.1158/1535-7163.MCT-08-0596 ID - Kolinsky2009 ER - TY - JOUR AU - Carmeliet, P. PY - 2003 DA - 2003// TI - Angiogenesis in health and disease JO - Nat Med VL - 9 UR - https://doi.org/10.1038/nm0603-653 DO - 10.1038/nm0603-653 ID - Carmeliet2003 ER - TY - JOUR AU - Casanovas, O. AU - Hicklin, D. J. AU - Bergers, G. AU - Hanahan, D. PY - 2005 DA - 2005// TI - Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors JO - Cancer Cell VL - 8 UR - https://doi.org/10.1016/j.ccr.2005.09.005 DO - 10.1016/j.ccr.2005.09.005 ID - Casanovas2005 ER - TY - JOUR AU - Matsuda, Y. AU - Ueda, J. AU - Ishiwata, T. PY - 2012 DA - 2012// TI - Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer JO - Patholog Res Int VL - 2012 ID - Matsuda2012 ER - TY - JOUR AU - Takayama, T. AU - Miyanishi, K. AU - Hayashi, T. AU - Sato, Y. AU - Niitsu, Y. PY - 2006 DA - 2006// TI - Colorectal cancer: genetics of development and metastasis JO - J Gastroenterol VL - 41 UR - https://doi.org/10.1007/s00535-006-1801-6 DO - 10.1007/s00535-006-1801-6 ID - Takayama2006 ER - TY - JOUR AU - Alessi, D. R. AU - Cuenda, A. AU - Cohen, P. AU - Dudley, D. T. AU - Saltiel, A. R. PY - 1995 DA - 1995// TI - PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo JO - J Biol Chem VL - 270 UR - https://doi.org/10.1074/jbc.270.46.27489 DO - 10.1074/jbc.270.46.27489 ID - Alessi1995 ER - TY - JOUR AU - Turke, A. B. AU - Song, Y. AU - Costa, C. AU - Cook, R. AU - Arteaga, C. L. AU - Asara, J. M. AU - Engelman, J. A. PY - 2012 DA - 2012// TI - MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-3747 DO - 10.1158/0008-5472.CAN-11-3747 ID - Turke2012 ER - TY - JOUR AU - Carracedo, A. AU - Ma, L. AU - Teruya-Feldstein, J. AU - Rojo, F. AU - Salmena, L. AU - Alimonti, A. AU - Egia, A. AU - Sasaki, A. T. AU - Thomas, G. AU - Kozma, S. C. PY - 2008 DA - 2008// TI - Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer JO - J Clin Invest VL - 118 ID - Carracedo2008 ER - TY - JOUR AU - Ebi, H. AU - Corcoran, R. B. AU - Singh, A. AU - Chen, Z. AU - Song, Y. AU - Lifshits, E. AU - Ryan, D. P. AU - Meyerhardt, J. A. AU - Benes, C. AU - Settleman, J. PY - 2011 DA - 2011// TI - Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers JO - J Clin Invest VL - 121 UR - https://doi.org/10.1172/JCI57909 DO - 10.1172/JCI57909 ID - Ebi2011 ER - TY - JOUR AU - Sarker, D. AU - Molife, R. AU - Evans, T. R. AU - Hardie, M. AU - Marriott, C. AU - Butzberger-Zimmerli, P. AU - Morrison, R. AU - Fox, J. A. AU - Heise, C. AU - Louie, S. PY - 2008 DA - 2008// TI - A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-1466 DO - 10.1158/1078-0432.CCR-07-1466 ID - Sarker2008 ER - TY - JOUR AU - Vogelstein, B. AU - Lane, D. AU - Levine, A. J. PY - 2000 DA - 2000// TI - Surfing the p53 network JO - Nature VL - 408 UR - https://doi.org/10.1038/35042675 DO - 10.1038/35042675 ID - Vogelstein2000 ER - TY - JOUR AU - Vousden, K. H. AU - Lu, X. PY - 2002 DA - 2002// TI - Live or let die: the cell’s response to p53 JO - Nat Rev Cancer VL - 2 UR - https://doi.org/10.1038/nrc864 DO - 10.1038/nrc864 ID - Vousden2002 ER - TY - JOUR AU - Cory, S. AU - Adams, J. M. PY - 2002 DA - 2002// TI - The Bcl2 family: regulators of the cellular life-or-death switch JO - Nat Rev Cancer VL - 2 UR - https://doi.org/10.1038/nrc883 DO - 10.1038/nrc883 ID - Cory2002 ER - TY - JOUR AU - Stiles, B. L. PY - 2009 DA - 2009// TI - PI-3-K and AKT: onto the mitochondria JO - Adv Drug Deliv Rev VL - 61 UR - https://doi.org/10.1016/j.addr.2009.07.017 DO - 10.1016/j.addr.2009.07.017 ID - Stiles2009 ER - TY - JOUR AU - Pennarun, B. AU - Kleibeuker, J. H. AU - Boersma-van Ek, W. AU - Kruyt, F. A. AU - Hollema, H. AU - de Vries, E. G. AU - de Jong, S. PY - 2013 DA - 2013// TI - Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL JO - J Pathol VL - 229 UR - https://doi.org/10.1002/path.4138 DO - 10.1002/path.4138 ID - Pennarun2013 ER - TY - JOUR AU - Longo, P. G. AU - Laurenti, L. AU - Gobessi, S. AU - Sica, S. AU - Leone, G. AU - Efremov, D. G. PY - 2008 DA - 2008// TI - The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells JO - Blood VL - 111 UR - https://doi.org/10.1182/blood-2007-05-089037 DO - 10.1182/blood-2007-05-089037 ID - Longo2008 ER - TY - JOUR AU - Altieri, D. C. PY - 2001 DA - 2001// TI - The molecular basis and potential role of survivin in cancer diagnosis and therapy JO - Trends Mol Med VL - 7 UR - https://doi.org/10.1016/S1471-4914(01)02243-2 DO - 10.1016/S1471-4914(01)02243-2 ID - Altieri2001 ER - TY - JOUR AU - Suzuki, A. AU - Ito, T. AU - Kawano, H. AU - Hayashida, M. AU - Hayasaki, Y. AU - Tsutomi, Y. AU - Akahane, K. AU - Nakano, T. AU - Miura, M. AU - Shiraki, K. PY - 2000 DA - 2000// TI - Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death JO - Oncogene VL - 19 UR - https://doi.org/10.1038/sj.onc.1203429 DO - 10.1038/sj.onc.1203429 ID - Suzuki2000 ER - TY - JOUR AU - Fondevila, C. AU - Metges, J. P. AU - Fuster, J. AU - Grau, J. J. AU - Palacin, A. AU - Castells, A. AU - Volant, A. AU - Pera, M. PY - 2004 DA - 2004// TI - p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer JO - Br J Cancer VL - 90 UR - https://doi.org/10.1038/sj.bjc.6601455 DO - 10.1038/sj.bjc.6601455 ID - Fondevila2004 ER - TY - JOUR AU - Krishnamachary, B. AU - Glunde, K. AU - Wildes, F. AU - Mori, N. AU - Takagi, T. AU - Raman, V. AU - Bhujwalla, Z. M. PY - 2009 DA - 2009// TI - Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-4120 DO - 10.1158/0008-5472.CAN-08-4120 ID - Krishnamachary2009 ER - TY - JOUR AU - Gaur, S. AU - Chen, L. AU - Yang, L. AU - Wu, X. AU - Un, F. AU - Yen, Y. PY - 2011 DA - 2011// TI - Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors JO - Cancer Lett VL - 311 UR - https://doi.org/10.1016/j.canlet.2011.06.005 DO - 10.1016/j.canlet.2011.06.005 ID - Gaur2011 ER - TY - JOUR AU - Gaur, S. AU - Chen, L. AU - Yen, T. AU - Wang, Y. AU - Zhou, B. AU - Davis, M. AU - Yen, Y. PY - 2012 DA - 2012// TI - Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer JO - Nanomedicine VL - 8 UR - https://doi.org/10.1016/j.nano.2011.09.007 DO - 10.1016/j.nano.2011.09.007 ID - Gaur2012 ER -